Cerebral GFAP is a central marker of AD: higher levels of GFAP in cortical gene and protein expression are associated with increased β-amyloid pathology, cerebral amyloid angiopathy, and faster cognitive decline, particularly in β-amyloid-positive individuals. Here, GFAP is linked to cerebral amyloid angiopathy.